Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43818
UPID:
U3IP2_HUMAN
Alternative names:
RRP9 homolog; U3 small nucleolar ribonucleoprotein-associated 55 kDa protein
Alternative UPACC:
O43818; B2R996; Q8IZ30
Background:
U3 small nucleolar RNA-interacting protein 2, also known as RRP9 homolog or U3 small nucleolar ribonucleoprotein-associated 55 kDa protein, plays a crucial role in pre-ribosomal RNA processing within the nucleolus. It is a component of the snoRNP complex and the SSU processome, facilitating RNA folding, modifications, rearrangements, and cleavage, essential for ribosome biogenesis.
Therapeutic significance:
Understanding the role of U3 small nucleolar RNA-interacting protein 2 could open doors to potential therapeutic strategies.